New data confirms AstraZeneca's confidence in Calquence
(Sharecast News) - AstraZeneca said on Monday that final results from the head-to-head 'ELEVATE-RR' phase 3 trial of 'Calquence', or acalabrutinib, demonstrated non-inferior progression-free survival (PFS) and statistically significantly fewer events of atrial fibrillation versus ibrutinib in adults with previously-treated chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults.
Read more